Why the study?
While aspirin has demonstrated a clear benefit in secondary prevention of coronary syndrome, its effect in primary prevention remains unclear.
Does aspirin prevent vascular events in patients without prior cardiovascular disease?
Does aspirin prevent vascular events in patients without prior cardiovascular disease?
Aspirin lacks clear benefit for primary prevention of cardiovascular events, with risks outweighing benefits in moderate to high-risk patients.
Aspirin not supported for primary prevention; leaves open targeted use in select low-risk groups.
Aspirin has demonstrated a clear benefit in secondary prevention of coronary syndrome, while aspirin's effect in primary prevention is unclear. This report will explore the role of aspirin as primary prevention for various vascular events. It strives to provide a clear guide for clinicians on whether or not to prescribe aspirin for their patients for primary prevention. Current guidelines and recent trials failed to show clear benefit against primary prevention, with risks outweighing benefits in moderate to high risk patients. A thoughtful discussion between patients and their doctors should be conducted before beginning aspirin use. More studies are needed to gain a better understanding of aspirin use in primary prevention.
No takes yet. Share an insight, caveat, or question.
Soodi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: